Fortive Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fortive Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $6.45B | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $5.76B | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $5.38B | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | Feb 25, 2026 |
| FY2025 | Sep 26, 2025 | $1.03B | Feb 25, 2026 |
| FY2025 | Jun 27, 2025 | $1.02B | Feb 25, 2026 |
| FY2025 | Mar 28, 2025 | $993.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.07B | Feb 25, 2026 |
| FY2025 | Sep 27, 2024 | $1.00B | Feb 25, 2026 |
| FY2025 | Jun 28, 2024 | $1.02B | Feb 25, 2026 |
| FY2025 | Mar 29, 2024 | $984.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $3.91B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $5.83B | Feb 25, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.81B | Feb 28, 2018 |
| FY2017 | Sep 29, 2017 | $1.69B | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $1.63B | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $1.54B | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $1.63B | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $1.57B | Feb 28, 2018 |
| FY2017 | Jul 1, 2016 | $1.56B | Feb 28, 2018 |
| FY2017 | Apr 1, 2016 | $1.47B | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $1.58B | Feb 28, 2017 |
| FY2016 | Oct 2, 2015 | $1.52B | Feb 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $708.90M | Feb 25, 2026 |
| FY2025 | Sep 26, 2025 | $649.20M | Feb 25, 2026 |
| FY2025 | Jun 27, 2025 | $645.50M | Feb 25, 2026 |
| FY2025 | Mar 28, 2025 | $637.50M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $695.50M | Feb 25, 2026 |
| FY2025 | Sep 27, 2024 | $641.50M | Feb 25, 2026 |
| FY2025 | Jun 28, 2024 | $653.60M | Feb 25, 2026 |
| FY2025 | Mar 29, 2024 | $628.50M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $2.48B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $3.36B | Feb 25, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $579.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $832.90M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $865.80M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $755.20M | Feb 25, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $225.50M | Feb 25, 2026 |
| FY2025 | Sep 26, 2025 | $159.60M | Feb 25, 2026 |
| FY2025 | Jun 27, 2025 | $169.80M | Feb 25, 2026 |
| FY2025 | Mar 28, 2025 | $165.30M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $212.20M | Feb 25, 2026 |
| FY2025 | Sep 27, 2024 | $172.00M | Feb 25, 2026 |
| FY2025 | Jun 28, 2024 | $182.30M | Feb 25, 2026 |
| FY2025 | Mar 29, 2024 | $149.80M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $574.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $987.40M | Feb 25, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $251.30M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $237.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $401.50M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $354.80M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $320.70M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $320.30M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $278.10M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $369.30M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $351.00M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.65B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.67B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.96B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $1.84B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.75B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.72B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $1.26B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.41B | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.27B | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.53B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.35B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.30B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $961.10M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.44B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.27B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $1.34B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.18B | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.14B | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $105.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $86.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $78.60M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $95.80M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $50.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $75.70M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $74.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $69.90M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $111.10M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $110.10M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.74B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $17.02B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $16.91B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $15.89B | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $16.47B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $16.05B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $17.44B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $12.91B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $10.50B | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $8.19B | Feb 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.45B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $10.19B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $10.32B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $9.68B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $9.51B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $8.96B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $7.39B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $6.60B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $3.79B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $2.69B | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.30B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.22B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.27B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $9.05B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $9.15B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $7.36B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $7.24B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $4.99B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $4.56B | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $3.45B | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.43B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.23B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $7.51B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $6.74B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.02B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $5.55B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $4.13B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $3.55B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.35B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $403.00M | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $375.50M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $813.30M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.89B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $709.20M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $819.30M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.82B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.21B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.18B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $962.10M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $803.20M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.21B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.71B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $3.65B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $3.25B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $3.96B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $4.23B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $6.33B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $3.43B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $4.06B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $3.36B | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Sep 26, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Jun 27, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Mar 28, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Sep 27, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Jun 28, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Mar 29, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 25, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Sep 26, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Jun 27, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Mar 28, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Sep 27, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Jun 28, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Mar 29, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 25, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 313.40M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 341.20M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 350.70M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 352.90M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 359.10M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 337.90M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 336.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 334.50M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 347.80M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 345.90M | Feb 28, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $111.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $102.00M | Feb 25, 2026 |
| FY2023 | Dec 31, 2022 | $99.50M | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $97.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $94.40M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $93.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $96.60M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $97.20M | Feb 27, 2020 |